Leap Therapeutics, Inc.
LPTX
$0.2924
-$0.0176-5.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.33% | -9.03% | -6.96% | -4.51% | -0.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.10% | 22.86% | -18.48% | -18.38% | -23.54% |
| Operating Income | 3.10% | -22.86% | 18.48% | 18.38% | 23.54% |
| Income Before Tax | -7.88% | -28.94% | 17.45% | 20.75% | 26.68% |
| Income Tax Expenses | -- | -- | -- | 381.63% | -- |
| Earnings from Continuing Operations | -8.85% | -30.04% | 16.74% | 20.02% | 26.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.85% | -30.04% | 16.74% | 20.02% | 26.81% |
| EBIT | 3.10% | -22.86% | 18.48% | 18.38% | 23.54% |
| EBITDA | 3.09% | -22.89% | 18.47% | 18.38% | 23.54% |
| EPS Basic | 20.24% | 28.27% | 63.78% | 66.19% | 69.44% |
| Normalized Basic EPS | 7.58% | 13.58% | 56.92% | 66.52% | 69.47% |
| EPS Diluted | 20.24% | 28.27% | 63.78% | 66.19% | 69.44% |
| Normalized Diluted EPS | 7.58% | 13.58% | 56.92% | 66.52% | 69.47% |
| Average Basic Shares Outstanding | 37.52% | 70.17% | 82.06% | 103.67% | 138.82% |
| Average Diluted Shares Outstanding | 37.52% | 70.17% | 82.06% | 103.67% | 138.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |